Ran Reshef, MD, MSc
Hematology/Oncology
Blood and Marrow Stem Cell Transplantation
Accepting New Patients
Virtual Visits/Telehealth
On the web
Overview
Dr. Ran Reshef trained in Hematology, Oncology, and Bone Marrow Transplantation and received a Master of Science degree in Translational Research from the University of Pennsylvania. He joined Columbia University in 2015 as Director of Translational Research for the Blood and Marrow Transplantation program. He is the Clinical Lead for the CAR-T Cell Program at Columbia, a principal investigator at the Columbia Center for Translational Immunology, and a member of the Herbert Irving Comprehensive Cancer Center.
Areas of Expertise / Conditions Treated
- Amyloidosis
- Bone Marrow Transplant
- Cancer Immunotherapy
- Cellular Therapy
- Leukemia
- Lymphoma
- Multiple Myeloma
Academic Appointments
- Professor of Medicine at CUMC
Administrative Titles
- Director of Translational Research, Blood and Marrow Transplantation Program
- Director of the Cell Therapy Program
Hospital Affiliations
- NewYork-Presbyterian / Columbia University Irving Medical Center
Languages
- Hebrew
Gender
- Male
Schedule an Appointment
Virtual Visits/Telehealth
Virtual Visits allow you to connect with your provider from the comfort, convenience, and safety of your own home.
Phone Appointments
New and Existing Patients:
Connect Patient Portal
For existing patients, login to make an appointment, view documentation or contact your care provider.
Location(s)
161 Fort Washington Avenue
New York, NY 10032
Phone:
Fax:
Insurance Accepted
Aetna
- Aetna Signature Administrators
- EPO
- HMO
- Medicare Managed Care
- NY Signature
- POS
- PPO
- Student Health
Affinity Health Plan
- Essential Plan
- Medicaid Managed Care
Amida Care
- Special Needs
Cigna
- EPO
- Great West (National)
- HMO
- Medicare Managed Care
- POS
- PPO
Emblem/GHI
- Medicare Managed Care
- PPO
Emblem/HIP
- ConnectiCare
- EPO
- Essential Plan
- HMO
- Medicaid Managed Care
- Medicare Managed Care
- POS
- PPO
- Select Care (Exchange)
- Vytra
Empire Blue Cross/Blue Shield
- EPO
- HMO
- Medicare Managed Care
- PPO
Empire Blue Cross Blue Shield HealthPlus
- Child/Family Health Plus
- Essential Plan
- Medicaid Managed Care
Fidelis Care
- Child/Family Health Plus
- Essential Plan
- Medicaid Managed Care
- Medicare Managed Care
Healthfirst
- Child/Family Health Plus
- Leaf (Exchange)
- Medicaid Managed Care
- Medicare Managed Care
Local 1199
- Local 1199
- NYP Employee Plan
MagnaCare (National)
- MagnaCare
Medicare
- Railroad
- Traditional Medicare
Multiplan
- Multiplan
MVP Health Care
- Child/Family Health Plus
- Essential Plan
- HMO
- Medicaid Managed Care
RiverSpring
- Special Needs
UnitedHealthcare
- Compass (Exchange)
- Empire Plan
- HMO
- Medicaid (Community Plan)
- Medicare Managed Care
- Oxford Freedom
- Oxford HMO
- Oxford Liberty
- POS
- PPO
VNSNY CHOICE
- Medicare Managed Care
- SelectHealth
- Special Needs
WellCare
- Medicaid Managed Care
- Medicare Managed Care
World Trade Center Health Plan
- World Trade Center Health Plan
*Before your appointment, please contact the doctor’s office or your insurance provider to verify that your insurance is accepted. This list of insurances can change, and the insurance plans listed may not be accepted at all office locations for this provider.
Credentials & Experience
Education & Training
- MD, 2003 Medicine, Sackler School of Medicine, Tel Aviv University (Israel)
- MSc, 2011 Translational Research, Perelman School of Medicine University of Pennsylvania
- Internship: 1998 Tel Aviv Sourasky Medical Center, Israel
- Residency: 2007 Tel Aviv Sourasky Medical Center, Israel
- Fellowship: 2009 Perelman School of Medicine University of Pennsylvania
Committees, Societies, Councils
- American Society of Clinical Oncology
- American Society of Hematology
- American Society of Blood and Marrow Transplantation
- Center for International Blood and Marrow Transplant Research
- Bone Marrow Transplant Clinical Trials Network Steering Committee
- Mount Sinai Acute GvHD International Consortium
- American Journal of Hematology (Editorial Board)
- National Institutes of Health (Study Section)
- Department of Defense (Study Section)
Honors & Awards
- 2008: Sternberg Research Award, Abramson Cancer Center, University of Pennsylvania
- 2011: Bradley Fellow Research Award, Department of Medicine, University of Pennsylvania
- 2012: Austrian Junior Faculty Award, Department of Medicine, University of Pennsylvania
- 2013: Amy Strelzer Manasevit Award for the Study of Post-Transplant Complications, National Marrow Donor Program
Research
The Reshef lab combines efforts in both basic research and clinical investigation to advance the understanding of immune responses following hematopoietic stem-cell transplantation and other forms of cell therapy.
Research Areas
- Investigating lymphocyte migration mechanisms and how they affect the clinical and immunologic outcomes of stem-cell transplantation. The lab pioneered the use of chemokine receptor blockade after allogeneic stem-cell transplantation to reduce immune-mediated complications.
- Developing methodologies for the study of human samples from transplant recipients at the single-cell level in order to unravel novel immunologic mechanisms that would lead to new therapeutic approaches. The lab works with blood, stool and tissue samples and uses a diverse toolset that includes genomic and immunophenotypic methods to identify new therapeutic modalities. Our ultimate goal is to identify new targets that improve transplant outcomes using evidence in both mice and humans and to test these targets clinically.
Grants
Dr. Reshef’s research is funded by the National Cancer Institute, Conquer Cancer Foundation, National Marrow Donor Program and Department of Defense. He previously received awards from the Leukemia & Lymphoma Society and the American Society of Hematology.
Selected Publications
- Reshef R, Luger SM, Hexner EO, Loren AW, Frey NV, Nasta, SD, Goldstein SC, Stadtmauer EA, Smith J, Bailey S, Mick R, Heitjan DF, Emerson SG, Hoxie J, Vonderheide RH, Porter DL (2012). "Effect of Blocking Lymphocyte Chemotaxis on Visceral Graft-vs-Host Disease." N Engl J Med 367:135-145
- Reshef R, Huffman AP, Gao A, Luskin MR, Hexner EO, Loren AW, Frey NV, Stadtmauer EA, Luger SM, Mangan JK, Nasta SD, Gill SI, Sell M, Kambayashi T, Richman LP, Vonderheide RH, Mick R, Porter DL (2015). "High Graft CD8 Cell Dose Predicts Improved Survival and Enables Better Donor Selection In Allogeneic Stem-Cell Transplantation With Reduced-Intensity Conditioning" J Clin Oncol 33:2392-2398.
- Ryan H. Moy, Austin P. Huffman, Lee P. Richman, Lisa Crisalli, Ximi K. Wang, James A. Hoxie, Rosemarie Mick, Stephen G. Emerson, Yi Zhang, Robert H. Vonderheide, David L. Porter and Ran Reshef (2017) "Clinical and immunologic impact of CCR5 blockade in graft-versus-host disease prophylaxis" Blood 129:906-916
- Mishkin AD, Mapara MY, Reshef R (2018). "Iatrogenic Infertility After Curative Stem Cell Transplantation in Sickle Cell Disease Patients". Ann Intern Med 2018 Jun 19;168(12):881-88
For a complete list of publications, please visit PubMed.gov